1-(4-乙基-3-羟基苯基)-乙酮 | 73898-20-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1-(4-乙基-3-羟基苯基)-乙酮
• 英文名称: 1-(4-ethyl-3-hydroxyphenyl)ethanone
• CAS: 73898-20-1
• 化学式: C₁₀H₁₂O₂
• 分子量: 164.204
• InChiKey: CHGLHDYZTVAACJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(4-乙基-3-羟基苯基)-乙酮 在 1,4-dioxane dibromide 作用下， 以 1,4-二氧六环 、 乙醚 为溶剂， 反应 2.0h， 以67%的产率得到2-Bromo-1-(4-ethyl-3-hydroxy-phenyl)-ethanone
  参考文献：
  名称：

  Synthesis and structure-activity relationships among .alpha.-adrenergic receptor agonists of the phenylethanolamine type

  摘要：

  Nineteen arylethanolamine derivatives related to norepinephrine were prepared and tested for alpha-adrenergic stimulant activity. In one series the analogues possess a p-hydroxy function, while the meta position is substituted by methyl, ethyl, isopropyl, chlohexyl, fluoro, chloro, iodo, carboxy, carbomethoxy, and methylsulfamido groups. The other series is meta hydroxylated with the para position substituted by the same groups. The influence of these groups upon the alpha-adrenergic activity is discussed, and the compounds are compared to octopamine, normetanephrine, norepinephrine, and norphenylephrine. It has been found that the introduction of an isopropyl, cyclohexyl, and fluoro group in the meta position of octopamine improves its affinity by three, five, and six times, respectively, whereas when these groups are introduced in the para position of norphenylephrine their effects are always detrimental. The most active compound, alpha-(aminomethyl)(4-fluoro-3-hydroxyphenyl)methanol (44), has about one-hundredth the affinity and the same intrinsic activity as norepinephrine.

  DOI：

  10.1021/jm00181a008
• 作为产物：
  描述：

  3'-氨基-4'-乙基-苯乙酮 在 硫酸 、 sodium nitrite 、 尿素 、 水 作用下， 以 水 为溶剂， 反应 1.5h， 生成 1-(4-乙基-3-羟基苯基)-乙酮
  参考文献：
  名称：

  WO2007/100880

  摘要：

  公开号：

文献信息

• Phosphodiesterase 10 inhibitors
  申请人：Arrington Mark P.

  公开号：US20090099175A1

  公开（公告）日：2009-04-16

  The present invention if directed to certain cinnoline compounds that are PDE10 inhibitors, pharmaceutical compositions containing such compounds and processes for preparing such compounds. The invention is also directed to methods of treating diseases mediated by PDE10 enzyme, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.

  本发明涉及某些具有PDE10抑制剂作用的茚啉化合物，包括含有这些化合物的制药组合物和制备这些化合物的方法。该发明还涉及通过PDE10酶介导的疾病的治疗方法，例如肥胖症、非胰岛素依赖性糖尿病、精神分裂症、双相情感障碍、强迫症等。
• WO2007/100880
  申请人：——

  公开号：——

  公开（公告）日：——
• OXIME ETHER COMPOUNDS, THEIR USE AND INTERMEDIATES FOR PREPARATIONS OF THE SAME
  申请人：Sumitomo Chemical Company, Limited

  公开号：EP0975587A1

  公开（公告）日：2000-02-02
• [EN] OXIME ETHER COMPOUNDS, THEIR USE AND INTERMEDIATES FOR PREPARATIONS OF THE SAME<br/>[FR] COMPOSES D'ETHER D'OXIME, LEUR UTILISATION ET INTERMEDIAIRES POUR LEUR PREPARATION
  申请人：SUMITOMO CHEMICAL COMPANY, LIMITED

  公开号：WO1998043949A1

  公开（公告）日：1998-10-08

  (EN) According to the present invention, there are provided oxime ether compounds represented by general formula (I). These compounds have excellent antifungal effect for agriculture and/or horticulture as well as excellent insecticidal and/or acaricidal effect.(FR) La présente invention concerne des composés d'éther d'oxime représentés par la formule (I). Ces composés présentent un effet antifongique excellent pour l'agriculture et/ou l'horticulture ainsi qu'un effet insecticide et/ou acaricide excellent.
• [EN] CINNOLINE AND QUINOXALINE DERIVATES AS PHOSPHODIESTERASE 10 INHIBITORS<br/>[FR] CINNOLINE ET DERIVES DE QUINOXALINE EN TANT QU'INHIBITEURS DE PHOSPHODIESTERASE 10
  申请人：AMGEN INC

  公开号：WO2007100880A1

  公开（公告）日：2007-09-07

  [EN] The present invention if directed to cinnoline and quinazoline compounds of formula (I) that are PDE10 inhibitors, pharmaceutical compounds containing the same and processes for preparing the same. The invention is also directed to methods of treating diseases mediated by PDE10 enzyme such as obesity, non-insulin dependent diabetes, schizophrenia or bipolar disorder, obsessive-compulsive disorder, and the like.
  [FR] La présente invention concerne des composés de cinnoline et de quinazoline de formule (I) constituant des inhibiteurs de PDE10, des compositions pharmaceutiques contenant de tels composés et des procédés de fabrication de tels composés. L'invention concerne également des procédés de traitement de maladies induites par l'enzyme PDE10, telles que l'obésité, le diabète non insulinodépendant, la schizophrénie, le trouble bipolaire, le trouble obsessionnel-compulsif et similaires.